Signed in as:
filler@godaddy.com
MI Capital Research Ltd, MICAP, established in 2013, is the UK’s leading provider of research and due diligence on tax advantaged alternative investments to the financial advisory and wealth management sector. A multi-award winning fin-tech platform, it provides sophisticated advisor tools to enable them to advise their clients compliantly, quickly and with confidence. MICAP was sold to Defaqto (Fintel Plc) in July 2024.
Founder, Investor and Director
Indagate Group Ltd was established in 2015 as a holding company following a merger of three financial business-information companies comprising MI Capital Research Ltd, Intelligent Partnership Ltd and SIPP Investment Platform Ltd. The Indagate group of companies are UK leaders in financial business information on alternative investments for the wealth management and financial advisory sector.
Owner, Investor and Director
Intelligent Partnership, established in 2008, is the UK’s leading provider of education and insights on alternative investments. Serving the entire advisory and fund management market, it hosts an extensive research hub, e-learning courses, weekly update briefings, fund manager showcases, live and digital events, champions industry campaigns and hosts the sector industry awards.
Owner and Investor
W9 Holdings Ltd is a property investment, development and management company with a current portfolio of 4 Mews Houses in Maida Vale, London. With experience in financial restructuring, planning, property development and letting, W9 Holdings invests in real estate development opportunities in central London.
Owner, Investor and Director
SIPP Investment Platform Ltd (trading as in-review) hosts an extensive directory of due diligence, research and reviews on alternative investment and alternative finance products since 2010. In-Review is trusted by SIPP operators, financial advisors, crowd-funding and asset finance platforms on non-standard assets.
Owner and Investor
GENUTEX Ltd, a UK start-up company, offers a unique AI-driven hybrid blockchain solution to enhance data collection and analysis in clinical trials and, using data encrypted app-based verification, to authenticate the pharmaceutical supply-chain and mitigate the global supply of counterfeit pharmaceuticals.
Non-Executive Director